
INTEGRA LIFESCIENCES HOLDING
IARTNASDAQTrading Snapshot
- Day Range
- $17.17 β $17.59
- 52-Week Range
- $8.70 β $20.49
- Volume
- $2.02B
- Avg Volume
- $2.25B
- Shares Outstanding
- 77.8M
- Next Earnings
- Sep 4, 2026
Fundamentals Snapshot
- Annual Revenue
- $1.64B
- Last Q Revenue
- $419M
- P/E Ratio
- -188.4
- P/S Ratio
- 0.8x
- EPS (TTM)
- $-0.09
- Dividend Yield
- 0.00%
Why Investors Own IART
- βHigh-growth profile β revenue up +31.8% YoY with expanding US Equity exposure.
- βHealthy economics β 79% gross margin and 23% free-cash-flow margin.
- βNew products and segments could unlock additional revenue streams.
Execution delays, intensifying competition, and valuation compression if growth decelerates.
Financial Trends
About INTEGRA LIFESCIENCES HOLDING
Integra LifeSciences Holdings Corporation is a medical technology company focused on the creation, production, and global distribution of advanced surgical implants and instruments. These products are utilized across various medical fields, including neurosurgery, limb reconstruction, and general surgical procedures. The company operates through two primary business segments: Codman Specialty Surgical and Tissue Technologies. The Codman Specialty Surgical division offers a comprehensive range of neurosurgical and neuro-critical care products. This includes specialized equipment for tissue ablation, dural repair solutions, cerebral spinal fluid management systems, intracranial monitoring tools, and cranial stabilization devices. Additionally, this segment provides surgical headlamps, various instrumentation, and supports these offerings with asset management software, technical assistance, and after-market services. Integra also supplies an extensive catalog of approximately 40,000 surgical instrument designs, along with a wide selection of surgical and lighting products. Its clientele spans hospitals, surgical centers, and extends to dental, podiatry, and veterinary practices. The Tissue Technologies segment specializes in innovative regenerative technology products for the treatment of both acute and chronic wounds. It further provides surgical tissue repair solutions for a multitude of applications, such as hernia repair, peripheral nerve protection and regeneration, and tendon reconstruction. This encompasses a broad array of offerings for skin and wound repair, plastic and reconstructive surgery products, bone grafting materials, and specialized nerve and tendon repair products. Integra LifeSciences distributes its diverse product portfolio internationally, reaching markets throughout the United States, Europe, Asia Pacific, and other global regions. Distribution is managed directly through its dedicated sales forces and various other channels, serving a wide array of healthcare entities including hospitals, integrated health networks, group purchasing organizations, individual clinicians, surgery centers, and other healthcare providers. Founded in 1989, Integra LifeSciences Holdings Corporation is headquartered in Princeton, New Jersey.
Otter Score Breakdown
βAnalyst Price Target
βLatest News & Updates
INTEGRA LIFESCIENCES HOLDING tops quarterly estimates as demand accelerates
Revenue grew double digits with management guiding above consensus; margins continued to expand.
Analysts lift IART price targets on improving margins
Several firms raised targets, citing stronger free cash flow and a healthier backlog.
INTEGRA LIFESCIENCES HOLDING announces new agreement to expand its footprint
The move broadens the companyβs reach and could add incremental revenue over the next year.